Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2140795 | Lung Cancer | 2015 | 5 Pages |
•EGFR-mutated lung adenocarcinoma belongs to the spectrum of predisposed neoplasms in LFS.•We provide the first description of resistance mutation to EGFR-TKI in a patient with LFS and lung adenocarcinoma.•Response to targeted therapy may benefit to the same extent to LFS patient as in the general population.
We report two cases of non-smoker patients diagnosed with EGFR-mutated lung adenocarcinoma and bearing germinal TP53 gene mutation, also known as Li-Fraumeni syndrome (LFS). We describe for the first time an EGFR-TKI resistance mutation in this population. Finally, we provide an analysis of discerning epidemiological data obtained from the IARC database and from all the published cases of EGFR-mutated lung cancer in TP53 germline mutation carriers.